Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Hallakou-Bozec S, et al. Among authors: moller de. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. Diabetes Obes Metab. 2021. PMID: 33269554 Free PMC article. Review.
Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.
Hallakou-Bozec S, Kergoat M, Moller DE, Bolze S. Hallakou-Bozec S, et al. Among authors: moller de. Endocrinol Diabetes Metab. 2020 Nov 7;4(2):e00193. doi: 10.1002/edm2.193. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2020. PMID: 33855202 Free PMC article.
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, Moller DE, Hallakou-Bozec S. Theurey P, et al. Among authors: moller de. Physiol Rep. 2022 Mar;10(5):e15151. doi: 10.14814/phy2.15151. Physiol Rep. 2022. PMID: 35274817 Free PMC article.
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.
Gluais-Dagorn P, Foretz M, Steinberg GR, Batchuluun B, Zawistowska-Deniziak A, Lambooij JM, Guigas B, Carling D, Monternier PA, Moller DE, Bolze S, Hallakou-Bozec S. Gluais-Dagorn P, et al. Among authors: moller de. Hepatol Commun. 2022 Jan;6(1):101-119. doi: 10.1002/hep4.1799. Epub 2021 Sep 7. Hepatol Commun. 2022. PMID: 34494384 Free PMC article.
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin JM, Chevalier C, Gluais-Dagorn P, Moller DE, Cusi K. Fouqueray P, et al. Among authors: moller de. Cell Rep Med. 2021 Dec 21;2(12):100474. doi: 10.1016/j.xcrm.2021.100474. eCollection 2021 Dec 21. Cell Rep Med. 2021. PMID: 35028615 Free PMC article. Clinical Trial.
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.
Monternier PA, Parasar P, Theurey P, Gluais Dagorn P, Kaur N, Nagaraja TN, Fouqueray P, Bolze S, Moller DE, Singh J, Hallakou-Bozec S. Monternier PA, et al. Among authors: moller de. J Pharmacol Exp Ther. 2022 Aug;382(2):208-222. doi: 10.1124/jpet.122.001208. Epub 2022 Jun 28. J Pharmacol Exp Ther. 2022. PMID: 35764327 Free PMC article.
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Cusi K, et al. Among authors: moller de. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):889-902. doi: 10.1016/S2468-1253(21)00300-9. Epub 2021 Sep 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34560015 Clinical Trial.
176 results